Exelixis (NASDAQ:EXEL) is a biotechnology company dedicated to the discovery, development, and commercialization of small molecule therapies for the treatment of cancer. Since its founding in 1994, Exelixis has been focused on applying cutting-edge genomics and molecular biology to identify novel targets and advance therapeutic candidates through clinical development. The company’s mission centers on delivering life-extending medicines to patients with serious diseases, with an emphasis on improving outcomes for individuals living with various forms of cancer.
The company’s core commercial products include Cometriq (cabozantinib) for medullary thyroid cancer and Cabometyx (cabozantinib) for renal cell carcinoma and hepatocellular carcinoma. Exelixis also co-develops and co-commercializes Cotellic (cobimetinib) in collaboration with Roche, which is approved for certain forms of metastatic melanoma. In addition to its marketed therapies, Exelixis maintains a robust pipeline of investigational agents targeting key pathways in oncology. Ongoing clinical programs explore the use of novel compounds in combination regimens and as monotherapies in multiple solid tumor types.
Headquartered in Alameda, California, Exelixis operates research and development facilities in the United States, Europe, and Asia. The company’s global footprint is supported by strategic collaborations with industry partners such as Ipsen, Takeda, and Roche, which help expand patient access and accelerate clinical trial execution across diverse geographies. Exelixis leverages a partnership-driven model to maximize the reach of its therapies while retaining in-house expertise in small molecule drug discovery and development.
Under the leadership of President and Chief Executive Officer Michael Morrissey, Exelixis continues to pursue innovation in oncology with a focus on both advancing existing assets and discovering new candidates. The executive team combines scientific rigor with commercial acumen to navigate regulatory pathways and bring life-saving treatments to market. With a commitment to research excellence and patient-centric development, Exelixis remains at the forefront of efforts to transform cancer care through precision medicine.
